Anti-Microbial Coatings to Prevent and Treat Infection at Indwelling or Implanted Medical Device Sites (RFT-232)

Generate a PDF of this technology.

Generate PDF

Invention Summary


Scientists at North Dakota State University have developed a polymer that can be incorporated into medical device materials and/or coatings, which enables local delivery of fluoroquinolone (FQ) antibiotics directly to the site of an indwelling or implanted medical device. The antibiotic is gradually released, providing immediate and ongoing anti-bacterial protection, (up to about 70 to 100 days). The technology is expected to be especially useful as a way to reduce infections that accompany inserted or implanted medical devices: It delivers antibiotic directly to the area at high risk of infection; it delivers antibiotic immediately so that infections are stopped early; and it allows for a smaller total dose with minimal systemic exposure so that many or most side effects of systemic delivery should be dramatically reduced.


  • Antibiotic is delivered directly to the medical device location, the area at greatest risk of infection
  • Higher local dosages may be realized as compared with systemic delivery, because delivery to non-target tissues is dramatically reduced or eliminated
  • Serious infections that develop after medical device implantation may be greatly reduced, because antibiotic is delivered immediately rather than waiting until symptoms develop (at which point bacterial colonies and biofilms may already have developed)
  • Rate of antibiotic release may be controlled by selection of specific moieties included in the tether between antibiotic and polysiloxane


The technology includes a polysiloxane backbone with fluoroquinolone antibiotics attached, and the entire complex then embedded in medical device polymers or coatings. Aspects of the technology include moieties that impact the conditions which lead to antibiotic release, and the rate of release into surrounding tissues.


This technology is the subject of issued US Patent No. 8,071,706 and US Patent No. 8,283,432 and is available for licensing and partnering opportunities.


Henry Nowak, Technology Manager


RFT, 232, RFT232

Inquire about this technology >